

## A Study to Compare Spirometric Observations in Smokers and Non Smokers in Age Group between 25-55 Years

Dr Kranti Randev<sup>1</sup>, Dr. K Ramesh Kumar<sup>2\*</sup>, Dr Ramshanker Reddy<sup>3</sup>, Dr A Siva Prasad<sup>4</sup>

<sup>1</sup>Senior Resident, Dept of Pulmonary Medicine, Bhaskar Medical College

<sup>2</sup>Professor & HOD, Dept of Pulmonary Medicine, Bhaskar Medical College

<sup>3</sup>Junior Resident, Dept of Pulmonary Medicine, Bhaskar Medical College

<sup>4</sup>Asst Professor, Dept of Pulmonary Medicine, Bhaskar Medical College

DOI: [10.36347/sasjm.2024.v10i05.001](https://doi.org/10.36347/sasjm.2024.v10i05.001)

| Received: 23.03.2024 | Accepted: 30.04.2024 | Published: 03.05.2024

\*Corresponding author: Dr. K Ramesh Kumar

Professor & HOD, Dept of Pulmonary Medicine, Bhaskar Medical College

### Abstract

### Original Research Article

In India, smoking is a common habit prevalent in both urban and rural areas irrespective of mode of smoking i.e beedis, cigarettes, cigars etc. Tobacco smoke contains 400 chemicals out of which 60 are known carcinogens, which can lead to lung cancer. Smoking leads to rapid decline in pulmonary function test. Cigarette smokers have a high annual rate of decline in FEV1 of about 50ml, which is nearly double the average value in non smokers.

**Keywords:** FEV1, FVC, PFT.

**Copyright © 2024 The Author(s):** This is an open-access article distributed under the terms of the Creative Commons Attribution **4.0 International License (CC BY-NC 4.0)** which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

## SUMMARY

The present study was conducted in department of pulmonary medicine Bhaskar medical college, Hyderabad in June 2022- June 2023. Based on our present study it was concluded that majority of smokers had normal lung function and a few had obstructive pattern in their FEV1/FVC ratio.

Cigarette smoking is the single cause of death in developing and developed countries. Smoking is now increasing throughout the world. It is one of the biggest threats to world health. For smokers, quitting smoking is the most important thing they can do to improve their health.

Most effective and cost effective thing is Encouraging smoking cessation.

It will prolong their patients' lives

### AIM

#### Objectives

- To study the influence of smoking in pulmonary function.
- To study the differences in spirometry findings in smokers and nonsmokers and their variations.
- To establish normal standards in healthy non smokers.

## METHODS

Informed and written consent will be taken from patient/guardian. Pulmonary function tests are assessed and results are analyzed in smokers and non smokers

### Study Population

- All smokers and smokers patients who come to Department of Pulmonary Medicine, Bhaskar Medical College and General Hospital.
- 50 smokers and 50 non smokers in the age group of 25-55 years.

### Inclusion Criteria

- Adult Male (25 to 55 years) with a history of cigarette/Bidi smoking dialy for atleast one year (case group)
- Adult male (25 to 55 years) with no past or present History of smoking taken as (Control group)

### Exclusion Criteria

- Females were not included in this study
- Smoking cessation candidates
- The known case of bronchial asthma
- The person who were morbid or have full fledged picture of cor pulmonale on clinical

**Citation:** Kranti Randev, K Ramesh Kumar, Ramshanker Reddy, A Siva Prasad. A Study to Compare Spirometric Observations in Smokers and Non Smokers in Age Group between 25-55 Years. SAS J Med, 2024 May 10(5): 305-309.

examination Person with known occupational lung diseases.

**Study Period**

Over a period of 12 months from June 2022 to June 2023

**Study Design Data Analysis (Expected Outcome)**

- Cross sectional study
- Data will be subjected to ANOVA statistical method using SPSS software 2023

**Ethical Implication**

- The study subjects will be selected following inclusion and exclusion criteria.
- Written & informed consent will be taken.

Every patient will be completely explained about the study and related procedures and their importance and complications in their own understandable language

**Financial Implication:** Funding–none

Expenses if any will be incurred by me

**Investigations:** Chest x ray

**Pulmonary Function Test:** Spirometry

**Statistical Analysis**

All the information obtained from our study population was collected and recorded in master chart. Statistical significance was analysed by Chi-square test and logistic regression analysis was performed with SPSS software to assess independent association of variables found to be significant in univariate analysis.

If the Pvalue is between 0.000 to 0.010, it is considered to be significant at level1- Highly Significant If the P value is between 0.011 to 0.050, it is considered to be significant at level 5- Significant If the P value is between 0.051-1.000, it is considered insignificant at level5- Not Significant.

**RESULTS**

**AGE DISTRIBUTION IN SMOKERS**

AGE IN YEARS	NO OF PATIENTS	PERCENTAGE
25 -35	9	18%
36 -45	10	20%
46-55	31	62%

In this Study About 62% of this study group belongs to age between 46-55 years.  
About 18% contributed persons belongs 25-35 year of age group.20% of persons belongs to age group 36-45 years.

**AGE DISTRIBUTION IN NON SMOKERS**

AGE IN YEARS	NO OF PATIENTS	PERCENTAGE
25 -35	3	6%
36 -45	16	32%
46-55	31	62%

In this Study About 62% of this study group belongs to age between 46-55 years .About 6%% contributed persons belongs 25-35 year of age group.32% of persons belongs to age group 36-45 years.

**SMOKING DURATION IN YEARS**

SMOKING DURATION IN YRS	NO OF PATIENTS	PERCENTAGE
< 20	22	44%
21-30	16	32%
>30	12	24%

Major part of members around 44% in less than 20 years of smoking duration.. Only 24% of participant have more than 30 years of smoking duration.

**FEV1 STAGES IN SMOKER PARTICIPANTS**

FEV1 STAGES	NO OF PATIENTS	PERCENTAGE
ABNORMAL	13	26%
NORMAL	37	74%

A total of 50 participant about 74% were have normal FEV1. Remining participant have abnormal values which is about 26%.

**FEV1 STAGES IN Non Smoker PARTICIPANTS**

FEV1 STAGES	NO OF PATIENTS	PERCENTAGE
ABNORMAL	2	4%
NORMAL	48	96%

A total of 50 participant about 96% were have normal FEV1. Remining participant have abnormal values which is about 4%.

**FEV1 STAGES IN SMOKER PARTICIPANTS**


FEV1 STAGES	NO OF PATIENTS	PERCENTAGE
ABNORMAL	13	26%
NORMAL	37	74%

A total of 50 participant about 74% were have normal FEV1. Remining participant have abnormal values which is about 26%.

**SMOKING DURATION VS FEV1**

SMOKING DURATION IN YRS	FEV1	
	NORMAL	ABNORMAL
<20	23	0
21-30	8	7
>30	7	5
KRUSKAL WALLIS TEST		
P VALUE - 0.001		
SIGNIFICANT		


Smoking duration and FEV1 abnormality statistically significant




**SMOKING PACK YRS VS FEV1/FVC**

SMOKING PACK YRS	FEV1/FVC	
	NORMAL	ABNORMAL
<20	25	0
21-30	20	1
>30	2	2
KRUSKAL WALLIS TEST		
P VALUE - 0.001		
SIGNIFICANT		

This study shows significant P value – 0.001 in KRUSKAL WALLIS TEST.





## DISCUSSION

In our study, a total of 100 males were selected, out of them 50 were smokers and 50 were non smokers. World health organisation (WHO) reported that tobacco smoking killed 100 million people world wide in 20th century and warned that it could kill one billion people around the world in 21st century also. By the early 2030, tobacco related deaths would increase to 10 million a year.

This was a study conducted in Bhaskar medical college hospital with 100 consecutive patients. The purpose of this study is to compare the spirometric observations in smokers and non smokers in the age group between 25-55 years.

In this study, a major group about 94% showed normal pattern, a minor group of about 6% showed abnormal obstructive pattern in FEV1/FVC criteria in smokers, where as in non smokers group 4% shows mild decrease in FEV1 and FVC with no obstructive pattern in FEV1/FVC ratio with (100%) normal result In this study, there is a significant airflow limitation in relation to pack years of smoking

This study shows significant P value – 0.001 in KRUSKAL WALLIS TEST

In a similar study by Dan Stanescu *et al.*, the middle aged smokers were at less risk of developing COPD, but smokers above the age of 50 years were at more risk of development of COPD which was comparable to our study.

A similar study was done in Canada which showed the prevalence of airway obstruction of about 4.6% in the Age of 55 – 64 years and 5% in 65 – 74 years which was comparable to this study.

## CONCLUSION

This study will show that early detection yield of COPD in increasing age (> 40 YR) and the quantity of smoking year make the screening method more cost effective in undiagnosed smokers.

In this study, 94% of smokers had normal lung function and 6% showed obstructive pattern in their FEV1/FVC LUNG ratio. Decline in FEF25-75% significant number of patients can be diagnosed as small airway disease.

Nearly 40% were observed as reduced FEF25-75% even though ratio was normal in 94% of patients. Whereas in non smokers 4% showed mild decrease in FEV1/FVC ratio with no obstructive pattern.

PFT done by spirometry in asymptomatic smokers is an important screening test to diagnose COPD as it can be detected as early as possible.

## REFERENCES

- Buffels, J., Degryse, J., Heyrman, J., & Decramer, M. (2004). Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. *Chest*, 125(4), 1394-1399.
- Fletcher, C., & Peto, R. (1977). The natural history of chronic airflow obstruction. *Br Med J*, 1(6077), 1645-1648.
- Global Initiative for Chronic Obstructive Lung Disease (COPD). Global strategy for the diagnosis, management and prevention of COPD: NHLBI/WHO Workshop Report. Bethesda: National Heart, Lung and Blood Institute; Publication No. 02-3659. Updated 2006.
- Goérecka, D., Bednarek, M., Nowinéski, A., Goljan-Geremek, A., & Zielinéski, J. (2003). Diagnosis of airflow limitation combined with smoking cessation

- advice increases stop-smoking rate. *Chest*, 123(6), 1916-1923.
- Jindal, S. K., Aggarwal, A. N., & Gupta, D. (2001). Disease and Its Association with Smoking. *Indian J Chest Dis Allied Sci*, 43, 139-471.
  - Jindal, S. K., Aggarwal, A. N., Chaudhry, K., Chhabra, S. K., D'Souza, G. A., Gupta, D., ... & Vijayan, V. K. (2006). A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. *The Indian journal of chest diseases & allied sciences*, 48(1), 23-29.
  - Jindal, S. K., Malik, S. K., & Dhand, R. (1983). Bronchogenic carcinoma in northern India. *Thorax*, 37, 343-47.
  - Lopez, A. D., Shibuya, K., Rao, C., Mathers, C. D., Hansell, A. L., Held, L. S., ... & Buist, S. (2006). Chronic obstructive pulmonary disease: current burden and future projections. *European Respiratory Journal*, 27(2), 397-412.
  - Mannino, D. M., Gagnon, R. C., Petty, T. L., & Lydick, E. (2000). Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. *Archives of internal medicine*, 160(11), 1683-1689.
  - Murray, C. J., & Lopez, A. D. (1997). Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. *The lancet*, 349(9064), 1498-1504.
  - Pande, J. N., & Khilnani, G. C. (1997). Epidemiology and aetiology, In: Shankar PS, ed. Chronic Obstructive Pulmonary Disease: *Indian College of Physicians*, 10-22.
  - Pietinalho, A., Kinnula, V. L., Sovijärvi, A. R. A., Vilkmann, S., Säynäjäkangas, O., Liippo, K., ... & Laitinen, L. A. (2007). Chronic bronchitis and chronic obstructive pulmonary disease. The Finnish Action Programme, interim report. *Respiratory medicine*, 101(7), 1419-1425.
  - Shapiro, D. S., Snider, G. L., & Rennard, S. I. (2000). In: Mason RJ, Murray JF, Broaddus V C, Nadel J A, editors. Textbook of Respiratory Medicine. Philadelphia: *Elsevier Saunders*, 1115-1167.
  - Society, A. T. (1995). Standardization of spirometry, 1994 update. *Am J Respir Crit Care Med*, 152(3), 1107-36.
  - Stratelis, G., Jakobsson, P., Molstad, S., & Zetterstrom, O. (2004). Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. *British Journal of General Practice*, 54(500), 201-206.
  - Zieliński, J., Bednarek, M., & Know the Age of Your Lung Study Group. (2001). Early detection of COPD in a high-risk population using spirometric screening. *Chest*, 119(3), 731-736.